ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Considerations for individualizing antihypertensive therapy

Considerations for individualizing antihypertensive therapy
Indication or contraindication Antihypertensive drugs
Compelling indications (major improvement in outcome independent of blood pressure)
Heart failure with reduced ejection fraction ACE inhibitor or ARB, beta blocker, diuretic, aldosterone antagonist*
Postmyocardial infarction ACE inhibitor or ARB, beta blocker, aldosterone antagonist
Proteinuric chronic kidney disease ACE inhibitor or ARB
Angina pectoris Beta blocker, calcium channel blocker
Atrial fibrillation rate control Beta blocker, nondihydropyridine calcium channel blocker
Atrial flutter rate control Beta blocker, nondihydropyridine calcium channel blocker
Likely to have a favorable effect on symptoms in comorbid conditions
Benign prostatic hyperplasia Alpha blocker
Essential tremor Beta blocker (noncardioselective)
Hyperthyroidism Beta blocker
Migraine Beta blocker, calcium channel blocker
Osteoporosis Thiazide diuretic
Raynaud phenomenon Dihydropyridine calcium channel blocker
Contraindications
Angioedema Do not use an ACE inhibitor
Bronchospastic disease Do not use a non-selective beta blocker
Liver disease Do not use methyldopa
Pregnancy (or at risk for) Do not use an ACE inhibitor, ARB, or renin inhibitor (eg, aliskiren)
Second- or third-degree heart block Do not use a beta blocker, nondihydropyridine calcium channel blocker unless a functioning ventricular pacemaker
Drug classes that may have adverse effects on comorbid conditions
Depression Generally avoid beta blocker, central alpha-2 agonist
Gout Generally avoid loop or thiazide diuretic
Hyperkalemia Generally avoid aldosterone antagonist, ACE inhibitor, ARB, renin inhibitor
Hyponatremia Generally avoid thiazide diuretic

ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker.

* A benefit from an aldosterone antagonist has been demonstrated in patients with NYHA class III-IV heart failure or decreased left ventricular ejection fraction after a myocardial infarction.
Adapted from: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289:2560.
Graphic 63628 Version 16.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟